Coronary Artery Calcium (CAC) Score: A Cardiologist's Guide to the Test, the Result, and What to Do

The coronary artery calcium (CAC) score is the most useful single test in modern preventive cardiology. It is cheap, fast, non-invasive, and gives direct anatomic evidence of coronary artery disease rather than the indirect probability estimate of a risk calculator. In my Encinitas practice, the CAC score has changed more conversations about cardiovascular prevention than any other tool over the past decade. This guide walks through how the test works, what the result means, when to order it, and how I use it in clinic.

What Is a Coronary Artery Calcium (CAC) Score?

A CAC score is a number, computed from a low-dose chest CT, that quantifies the total amount of calcified atherosclerotic plaque in the coronary arteries. It is a direct anatomic measurement of coronary artery disease, not an indirect probability estimate.

Risk calculators like the Pooled Cohort Equations, the ASCVD Risk Estimator Plus, and the SCORE2 algorithm estimate 10-year cardiovascular event risk from age, sex, blood pressure, LDL, HDL, smoking status, and diabetes. They are good population tools but mediocre individual tools, two patients with identical risk-factor profiles can have very different actual disease burdens.

The CAC score answers a different question: how much calcified plaque is actually in your coronary arteries right now? Calcium in the coronaries is a marker of mature atherosclerotic plaque. It does not appear in healthy coronary arteries. Its presence and amount have been mapped directly to event rates in large cohort studies including MESA (Multi-Ethnic Study of Atherosclerosis), CARDIA, and the Heinz Nixdorf Recall Study. A patient with a high CAC score has more atherosclerosis, full stop. That direct anatomic evidence is what makes the test so much more clinically useful than a calculator.

How Is a CAC Score Test Performed?

You lie on a CT scanner for about 10 minutes while a fast, ECG-gated CT scans your chest. No IV, no contrast, no fasting required. The radiation dose is about 1 mSv, equivalent to a few chest X-rays. Specialized software then quantifies the calcium signal in each coronary artery, generating the Agatston score.

The patient lies supine on the CT table with electrodes placed for ECG gating. The scanner triggers image acquisition at end-diastole, when the heart is briefly motionless between beats, so the coronary arteries are sharp rather than blurred. The whole scan takes a few seconds of breath-hold; the visit takes about 10 minutes start to finish.

Calcium appears bright white on the CT image because of its high attenuation. The software identifies pixels above a defined Hounsfield-unit threshold (typically 130 HU) within the territory of each coronary artery, multiplies the area of each calcified lesion by a density factor, and sums the result across all coronaries to produce the Agatston score. The output is a single number plus a per-vessel breakdown (left main, left anterior descending, circumflex, right coronary).

The radiation dose is about 1 mSv, comparable to the natural background radiation an average American receives over four months, and substantially less than a diagnostic chest CT or coronary CT angiogram. The procedure is well validated, reproducible across modern scanners, and standardized internationally. Results from one accredited center are directly comparable to results from another.

What Does My CAC Score Mean?

The Agatston score falls into five bins that drive clinical decisions. A score of 0 is a strong negative finding (very low 10-year event risk). A score of 100 or more is a strong indication for statin therapy regardless of LDL value. A score above 400 represents severe coronary plaque burden.

CAC Score Bins and Clinical Implications

A CAC score of zero is the “powerful negative” finding from the MESA cohort, less than 1% annual cardiovascular event risk over the subsequent 10 years. In selected patients at intermediate calculated risk, a zero score can support deferring statin therapy and focusing on lifestyle modification. Zero is not a guarantee for life, soft, non-calcified plaque can exist below the detection threshold, and CAC tends to accumulate with age, so the result should be repeated in 5 to 10 years if the patient remains at intermediate clinical risk.

A score of 1–99 indicates mild calcified plaque. Treatment decisions in this range depend on age, family history, Lp(a), and other risk-enhancing factors. A 45-year-old with a CAC of 50 is in roughly the 75th percentile for age, that is early atherosclerosis and a strong nudge toward statin therapy. The same score in a 75-year-old is below the 25th percentile and may not change management.

A score of 100 or more puts the patient into a treatment-required category by current guidelines. The 2018 ACC/AHA cholesterol guideline and 2019 ACC/AHA primary prevention guideline both elevate statin therapy to a Class IIa recommendation at CAC ≥ 100 regardless of calculated risk. I aim for an LDL below 70 mg/dL in these patients. Above 400, the patient is functionally a secondary-prevention case even without a prior event, and below 55 mg/dL is the right LDL target.

Above 1000, I add additional testing to the conversation, a stress test or coronary CT angiogram if there are any symptoms, and a careful review of antiplatelet therapy and aggressive lipid management.

The percentile relative to age- and sex-matched peers also matters. The MESA Risk Calculator (available free online) reports both the absolute CAC score and the percentile. A 50-year-old man with CAC of 100 is in roughly the 75th percentile for his age and sex; the same score in an 80-year-old woman is below the 50th percentile. Percentile context shapes the urgency of intervention.

Who Should Get a CAC Score?

CAC scoring is most useful for adults age 40–75 at intermediate 10-year ASCVD risk (between 5% and 20% on the Pooled Cohort Equations or similar calculator), where the result will meaningfully change whether you start a statin. It is not appropriate for low-risk young adults, for patients with already-established coronary disease, or for patients whose treatment plan is already set.

The ideal candidate is the patient sitting on the fence about statin therapy. A 55-year-old man with an LDL of 130 mg/dL, blood pressure 134/82, no diabetes, no family history, and a calculated 10-year ASCVD risk of 9% is exactly the kind of borderline case where current guidelines suggest “consider statin” and patients want more information before committing. A CAC of 0 in that patient supports deferral and lifestyle intensification. A CAC of 200 makes the statin a clear decision.

Borderline-risk patients (5–7.5% 10-year risk) with risk-enhancing factors, family history of premature CAD, metabolic syndrome, chronic inflammatory disease, elevated Lp(a), or persistent dyslipidemia, are another important group. In these patients, a CAC score often provides the deciding piece of information.

Strong family history of premature coronary disease (men under 55, women under 65) shifts the calculus toward earlier testing, sometimes in patients as young as their late 30s if familial hypercholesterolemia is on the table. The same is true for very elevated Lp(a), which carries lifetime risk that calculators based on LDL do not capture.

The patients who should not get a CAC score are those whose treatment is already set. A patient with established CAD, prior heart attack, prior PCI, or prior CABG already has a Class I indication for high-intensity statin therapy; the CAC score adds nothing. A patient already on appropriate statin therapy with well-controlled LDL is in the same situation. A patient at very low calculated risk (under 5%) is unlikely to have meaningful calcium and would not change management even if some were found. A patient with active chest pain or other symptoms suggestive of obstructive coronary disease needs a stress test or coronary CT angiogram, not a CAC score.

How Does the CAC Score Change Treatment?

A high CAC score (≥ 100) shifts the treatment threshold downward, aggressive statin therapy is indicated even at LDL values that would otherwise be considered borderline, and the goal LDL drops to below 70 mg/dL. A CAC of 0 in the right patient can permit deferring statin therapy or extending the follow-up interval. CAC results frequently change the conversation in my Encinitas practice.

A patient who walks in undecided about statin therapy and walks out with a CAC of 0 often leaves the visit motivated to intensify lifestyle, knowing that the calcium score is reassuring but not a permanent license to ignore LDL. A patient who walks in similarly undecided and walks out with a CAC of 250 typically goes home with a statin prescription and a much clearer sense of why it matters.

The CAC score also recalibrates other treatment decisions. Blood pressure targets become tighter, I aim for below 130/80 mmHg in patients with meaningful CAC. Diabetes management becomes more aggressive, with strong consideration for an SGLT2 inhibitor or GLP-1 receptor agonist that carries cardiovascular benefit. For patients with significant calcium and acceptable bleeding risk, I consider low-dose aspirin, though aspirin for primary prevention has become a much narrower indication after the ASPREE, ARRIVE, and ASCEND trials.

CAC scoring also shapes follow-up cadence. Patients with significant calcium need more frequent risk-factor monitoring, often every 3 to 6 months until LDL, blood pressure, and A1c are at target.

The CAC score is one piece of an integrated risk picture, not a free-standing diagnosis. I always interpret it alongside traditional risk factors, family history, Lp(a), hsCRP, apoB, and lifestyle context. Used that way, it is one of the most decision-relevant data points in preventive cardiology. The 2026 ACC/AHA cholesterol guideline leans further into this kind of personalized, lifetime-risk assessment with its new PREVENT calculator.

What Are Common Misconceptions About the CAC Score?

The biggest misconceptions are that CAC scoring is the same as a CT angiogram (it is not, CAC uses no contrast and shows only calcified plaque), that a high score means you need a stent (it does not, most high-CAC patients have stable disease and need medical therapy), that a score of 0 means you never need to worry about your heart again (it does not, soft plaque can exist below detection threshold), and that the test is dangerous from radiation (it is not, the dose is similar to a few chest X-rays).

CAC is not a CT angiogram. The two studies are often confused. A CAC scan is a non-contrast, low-dose CT that detects only calcified plaque. A coronary CT angiogram (CCTA) uses an IV contrast dye to visualize both calcified and non-calcified plaque and to map the lumen of each artery, meaning it can identify specific obstructive stenoses. CAC is a screening tool for asymptomatic risk stratification. CCTA is a diagnostic tool for symptomatic patients or those needing anatomic detail. The two answer different questions.

A high CAC score does not directly mean a stent. CAC quantifies plaque burden, not stenosis severity. A patient can have a CAC of 800 and only mild luminal narrowing on a subsequent angiogram, the calcium is mostly in non-flow-limiting plaque. The right response to a high CAC in an asymptomatic patient is aggressive medical therapy, not a catheterization or stent.

A CAC of 0 does not provide lifetime protection. It reflects no detectable calcified plaque at the time of the scan. Soft, non-calcified plaque can be present below detection threshold, and calcium can develop over time. The result is reassuring but not absolute. For most patients with intermediate risk and a CAC of 0, I repeat the scan in 5 to 10 years.

The radiation dose is small and the test is safe. At about 1 mSv, the lifetime cancer risk attributable to a single CAC scan is extremely low. The average American absorbs about 3 mSv of natural background radiation every year. A CAC scan is among the lower-dose cardiac CT studies and is safe for the indications described above.

Calcium does not “dissolve” with medical therapy. Existing calcium does not regress with treatment. In fact, the CAC score may slowly rise on a statin because soft plaque calcifies as it stabilizes; this is a sign of treatment working at the histological level, not failing. The right way to track statin response is LDL reduction, not CAC change.

What Are the Limitations of the CAC Score?

The CAC score measures only calcified plaque, it cannot detect soft, non-calcified plaque that may still rupture and cause a heart attack. It does not measure stenosis severity, so a high CAC score does not by itself tell us whether any specific blockage is flow-limiting. CAC scoring is also less informative in patients under age 40 or over age 80, where the test characteristics shift.

The single most important limitation is that CAC scoring only sees calcified plaque. Young adults, smokers, and patients with diabetes are more likely to have significant soft (non-calcified) plaque that does not show up on a CAC scan. A 38-year-old smoker with a CAC of 0 is not necessarily plaque-free, the test simply cannot rule out soft plaque at that age and risk profile. In those patients, a coronary CT angiogram or careful longitudinal follow-up is more informative.

CAC also does not tell us about stenosis severity. Two patients with a CAC of 600 can have very different obstructive disease, one with diffuse non-flow-limiting plaque and one with a critical proximal LAD stenosis. The CAC score is a sum of plaque burden, not a map of where the blockages are. When stenosis severity matters clinically, a coronary CT angiogram or functional test (stress echo, nuclear stress test, or stress MRI) is required.

The test does not predict timing of events with precision. A patient with a CAC of 400 is at higher 10-year risk than a patient with a CAC of 50, but neither score predicts which year, or whether, any specific event will occur. CAC is a population-level risk stratifier applied to an individual.

The test characteristics also shift at the extremes of age. Below age 40, CAC is usually 0 even in patients with significant atherosclerosis, soft plaque dominates. Above 80, CAC is usually present even in patients at low absolute event risk, accumulated lifetime exposure rather than active disease.

When Is CAC Scoring Inappropriate?

CAC scoring should not be ordered for low-risk young adults (under age 40 unless familial hypercholesterolemia is suspected), for patients with known coronary disease (the result will not change management), or for patients with symptomatic chest pain (a stress test or coronary CT angiogram is more useful). It is also redundant if a recent chest CT for any other reason already showed coronary calcium.

A patient with known CAD, a prior heart attack, prior PCI, or prior CABG already has a Class I indication for high-intensity statin therapy. Whatever the CAC score is, the treatment plan does not change. Ordering the test in those patients only adds cost and radiation without clinical benefit.

A patient with very high calculated 10-year risk (above 20%) is already a clear statin candidate. A patient with very low calculated risk (under 5%) is unlikely to have meaningful calcium and would not change management even if some were found. The test is most useful in the intermediate range where it actually moves the decision.

A patient with active chest pain or other symptoms suggestive of obstructive coronary disease needs a different test, not a CAC score. The CAC score does not assess whether a blockage is flow-limiting, and using it as a substitute for functional or anatomic testing in symptomatic patients delays diagnosis. For these patients, a stress test or coronary CT angiogram is the right next step.

Patients who are not candidates for statin therapy (severe statin intolerance, advanced liver disease, pregnancy) and who would not take a non-statin alternative either may also not benefit from the test, since the result cannot change management.

Finally, the test is redundant if a recent chest CT performed for any reason (lung cancer screening, pulmonary nodule follow-up, evaluation of dyspnea) has already commented on the presence and amount of coronary calcium. Modern radiology reports increasingly include a qualitative CAC estimate from any chest CT, that is often sufficient for the clinical purpose.

How Should You Handle a High CAC Score Emotionally?

A high CAC score is information, not a diagnosis of impending heart attack. It identifies you as someone who will benefit most from preventive therapy, and modern preventive therapy is extremely effective. The expected response to a high score is action (start a statin, optimize blood pressure, address lifestyle), not panic. Patients who lean into the data and treat aggressively have outcomes very different from patients with the same score who do nothing.

The pattern I see in clinic is that a CAC of 400 or more is initially upsetting and ultimately motivating. Patients who walk in unsure about taking a statin often walk out willing to start, and the visible evidence of disease tends to lock in lifestyle changes that had been intermittent. The Mayo Clinic and other large centers have published on this phenomenon, patients in the highest CAC categories who actually take their medications and adhere to lifestyle changes can reduce their event rates by 50% or more.

The opposite mistake is to treat a low or zero CAC as a license to ignore other risk factors. A 50-year-old with a CAC of 0 and an LDL of 180 mg/dL still has a high lifetime risk because of the cumulative LDL exposure; the absence of calcium today does not change the trajectory. CAC is one data point in a longer story.

Patients who get fixated on the exact number, “what does a 47 mean versus a 52”, are often missing the practical point. The bins matter more than the precise value. The action plan is the same for CAC 47 and CAC 52.

The emotional response I aim for is engaged rather than fearful. The test gives you actionable information, and the action is straightforward.

How Does CAC Scoring Fit Into Overall Cardiovascular Care?

The CAC score is one input into a broader risk picture that includes traditional risk factors (LDL, blood pressure, diabetes, smoking, family history), lipoprotein(a), hsCRP, apoB, and lifestyle. The score does not replace those, it integrates with them. I use CAC most often as the deciding factor when a patient is right at the statin-treatment threshold and unsure whether to commit.

The CAC score is the most useful single non-traditional risk marker in current cardiology. It is not the only one. A one-time lipoprotein(a) level identifies patients with a genetically high lifetime risk that LDL-based calculators miss entirely. Apolipoprotein B (apoB) gives a more accurate count of atherogenic particles than LDL-C alone, especially in patients with metabolic syndrome or high triglycerides. High-sensitivity C-reactive protein (hsCRP) flags inflammatory drivers of risk.

For a patient who is on the fence about statin therapy, I typically order all four, lipid panel with apoB, Lp(a), hsCRP, and a CAC score, before the next visit. The integrated picture almost always converges on a clear recommendation.

CAC scoring also informs how I monitor patients on treatment. Patients with a high baseline CAC who start aggressive statin therapy will see their LDL drop and their atherosclerotic disease stabilize, even though the CAC score may slowly rise (calcification of stabilizing soft plaque). I track LDL, blood pressure, and A1c every 3 to 6 months in these patients, and I do not repeat the CAC score routinely, the baseline value has already told us what we need to know.

For my Encinitas practice, the workflow is straightforward: a borderline or intermediate-risk adult age 40 to 75 gets a CAC score before we make a definitive decision on statin therapy. The result almost always resolves the question.

What’s Next for CAC Scoring?

The most active areas in 2026 are AI-augmented CAC scoring from non-gated chest CTs (turning every chest CT into an opportunistic risk assessment), CAC progression tracking to refine treatment monitoring, and combined plaque-and-stress assessment using AI on standard CT scans. Expect CAC to become a routine output of any chest imaging within the next 3 to 5 years.

AI-based opportunistic CAC scoring is the most consequential near-term development. Every CT chest done for any reason, lung cancer screening, pulmonary nodule follow-up, pulmonary embolism rule-out, contains coronary calcium information that has historically been ignored. AI tools (some now FDA-cleared) can quantify CAC automatically from these scans without additional imaging or radiation. This effectively turns every chest CT into a free CAC score, which will dramatically expand the population identified with subclinical atherosclerosis.

Plaque-morphology analysis is moving beyond simple calcium quantification. AI-based tools can now characterize plaque composition (calcified, lipid-rich, fibrous), identify high-risk features (low-attenuation plaque, positive remodeling, napkin-ring sign), and produce a more nuanced risk estimate than the Agatston score alone. These tools are most mature in the coronary CT angiogram space but will extend into CAC scoring as well.

Serial CAC tracking is being explored to monitor the rate of plaque progression as a real-time marker of treatment effectiveness. Slow CAC progression on statin therapy is reassuring; rapid progression despite optimal medical therapy may identify patients who need additional intervention. The methodology is not yet routine, but high-volume cardiology centers are increasingly using it for selected patients.

Integration of CAC scoring with polygenic risk scores and other genomic risk markers is in active research, particularly for younger adults where the CAC score itself is often zero but the lifetime risk is meaningfully elevated. Combined approaches may eventually identify the high-risk young adult who would benefit from earlier preventive intervention.

How Should You Decide About Getting a CAC Score?

Order one if you are between 40 and 75, have intermediate cardiovascular risk on a calculator (5–20% over 10 years), are uncertain about starting a statin, and would actually act on a high or low result. Skip it if you are already on the right treatment, if you are very high or very low risk, or if the result would not change anything.

The decision is best framed as: will the result of this test change what you do next? If the answer is yes, the test is worth doing. If the answer is no, the test is not worth doing.

Practical decision steps:

• Calculate your 10-year ASCVD risk using the Pooled Cohort Equations or the ASCVD Risk Estimator Plus.
• If your risk is intermediate (5–20%) and you are between 40 and 75, the CAC score is likely to change the conversation.
• If you have strong family history of premature CAD (men under 55, women under 65), elevated Lp(a), or metabolic syndrome, the threshold for getting a CAC score is lower.
• If you have already had a heart attack, stent, or CABG, you do not need a CAC score, you need high-intensity statin therapy.
• If you have chest pain or symptoms suggestive of obstructive disease, you need a stress test or coronary CT angiogram, not a CAC score.

Cost is rarely the limiting factor. Most US imaging centers offer self-pay rates of $75–$200, which is accessible for most patients who want the test. Insurance typically does not cover it as a routine screening test, but coverage is sometimes available when ordered for a specific clinical indication (familial hypercholesterolemia evaluation, etc.).

In my Encinitas practice, the most common scenario is a patient between 45 and 65 with borderline cholesterol, no family history, and uncertainty about whether to start a statin. A $100 CAC score almost always resolves that uncertainty in a single visit.

CAC Score: The Bottom Line

The coronary artery calcium score is one of the most useful single tests in modern preventive cardiology. It is cheap, fast, non-invasive, and provides direct anatomic evidence of CAD. When ordered in the right patient, intermediate-risk adult age 40 to 75, it almost always changes the conversation. Used well, it has prevented countless heart attacks in patients who would otherwise have been on the fence about statin therapy.

If you are between 40 and 75, have intermediate cardiovascular risk on a calculator, and are not already on appropriate preventive therapy, ask your cardiologist or primary care physician about a CAC score. It is one of the cheapest, fastest, and most informative tests you can do for your long-term heart health.

Frequently Asked Questions About the Coronary Artery Calcium Score

What is the difference between a CAC score and a CT angiogram?

A CAC score uses a non-contrast, low-dose chest CT to quantify calcified plaque only. A coronary CT angiogram (CCTA) uses contrast dye through an IV to visualize both calcified and non-calcified plaque AND the lumen of each coronary artery, meaning it can identify specific blockages. CAC scoring is for risk stratification in asymptomatic patients; CCTA is typically for symptomatic patients or those needing detailed anatomy.

Is a CAC score covered by insurance?

Most commercial insurance in the US does not cover routine CAC scoring as a screening test. Medicare also does not cover it for screening. Many imaging centers offer self-pay rates of $75–$200, making it accessible for most patients who want one. If your physician orders it for a specific clinical indication (familial hypercholesterolemia evaluation, etc.), coverage may be available.

Can the CAC score go down with treatment?

The calcified component of plaque does not regress meaningfully with current therapies. In fact, paradoxically, the calcium score may slowly increase on a statin because soft plaque calcifies as it stabilizes, this is a sign of treatment working, not failing. The right way to assess statin response is LDL reduction, not CAC change. Some advanced cardiology centers track CAC progression rate over years.

Is 1 mSv of radiation safe?

Yes, for this indication. The lifetime cancer risk from 1 mSv is extremely small. The average American is exposed to about 3 mSv of natural background radiation every year. CAC scoring is one of the lower-radiation cardiac CT studies.

At what age should I get a CAC score?

For most adults, age 40–55 is the prime window, early enough that intervention can change the trajectory, late enough that the test reliably picks up disease. Younger adults with a strong family history of premature CAD or familial hypercholesterolemia may benefit from earlier testing. Adults over 75 with no prior known CAD may also benefit, but the result less often changes management.

What does it mean if my CAC score is 0 but I have high cholesterol?

A CAC of 0 in a patient with high cholesterol is reassuring, it means despite an elevated LDL, atherosclerosis has not yet calcified in your coronary arteries. It may permit deferring or delaying statin therapy in selected lower-risk patients. However, soft (non-calcified) plaque can still be present below detection threshold, particularly in younger patients or those with very high Lp(a). The CAC = 0 finding is a “negative” worth respecting but not absolute permission to ignore the cholesterol.

Can I get a CAC score if I have a pacemaker or other metal in my chest?

Usually yes. Modern multi-detector CT scanners can typically work around pacemakers, ICDs, sternal wires from prior bypass surgery, and other metal hardware, though image artifact can sometimes reduce accuracy. Discuss your specific situation with the imaging center beforehand.

Should my children be tested if my CAC score is high?

Not based on your CAC score alone. Children with a family history of premature coronary disease (men < 55, women < 65) should be screened with a lipid panel in late adolescence and may benefit from earlier statin initiation if familial hypercholesterolemia is found. CAC scoring is not standard in children or young adults.

References

1. Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk. Journal of the American College of Cardiology. 2018;72(4):434-447.

2. Detrano R, Guerci AD, Carr JJ, et al. Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups (MESA). New England Journal of Medicine. 2008;358(13):1336-1345.

3. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology. 2019;74(10):e177-e232.

4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285-e350.

5. Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease (MESA). Circulation. 2016;133(9):849-858.

6. Erbel R, Möhlenkamp S, Moebus S, et al. Coronary Risk Stratification, Discrimination, and Reclassification Improvement Based on Quantification of Subclinical Coronary Atherosclerosis (Heinz Nixdorf Recall). Journal of the American College of Cardiology. 2010;56(17):1397-1406.

7. McEvoy JW, Martin SS, Dardari ZA, et al. Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy. Circulation. 2017;135(2):153-165.

8. Mortensen MB, Falk E, Li D, et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. JACC: Cardiovascular Imaging. 2018;11(2 Pt 1):221-230.

9. Nasir K, Cainzos-Achirica M. Role of Coronary Artery Calcium Score in the Primary Prevention of Cardiovascular Disease. BMJ. 2021;373:n776.

10. Hecht H, Blaha MJ, Berman DS, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography. Journal of Cardiovascular Computed Tomography. 2017;11(2):157-168.